The validity of the Hamilton and Montgomery-�sberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease

Leentjens, Albert F.G.; Verhey, Frans R.J.; Lousberg, Richel; Spitsbergen, Harro; Wilmink, Frederik W.

doi:10.1002/1099-1166(200007)15:7<644::aid-gps167>3.0.co;2-l

Cited by 262 publications

(198 citation statements)

References 30 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…One alternative scale, MADRS, was 'designed to be sensitive to change' (Montgomery and Asberg, 1979), but its use is not as widespread as HAM-D. A recent retrospective study found that it was as sensitive an instrument as HAM-D for detecting antidepressant efficacy (Khan et al, 2002), but there is currently no compelling evidence that it is superior to HAM-D in geriatric populations. In fact, one study examining a small sample of elderly patients with Parkinson's disease concluded that HAMD-17 exhibited slightly better diagnostic performance than did MADRS (Leentjens et al, 2000).…”

Section: Methodological Considerations For Antidepressant Trials In Tmentioning

confidence: 99%

A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future

Taylor

Doraiswamy

2004

Neuropsychopharmacol

View full text Add to dashboard Cite

Depression in the elderly is a major public health problem as untreated depression adversely impacts comorbid illnesses. It is important to develop safe and effective antidepressant therapies for older individuals. We performed a systematic review of all published randomized, placebo-controlled antidepressant medication trials in populations over age 55 years. Papers were obtained via MEDLINE (1966( -August 2003 and PSYCINFO (1872-August 2003. Unpublished trials, trials examining nonpharmacologic interventions, and papers reporting post hoc analyses were not included in this review unless they provided new insights. A total of 18 placebo-controlled trials examining acute efficacy met our criteria. The combined sample size in these studies was 2252. The mean sample size was 51 (range 20-728) and mean trial duration was 7 weeks. A total of 12 trials examined tricyclic antidepressants (TCAs), five trials examined selective serotonin reuptake inhibitors (SSRIs), two trials examined bupropion, and one trial examined mirtazapine. There were no published trials of venlafaxine or nefazodone. In all, 71.5% of trials reported significantly greater efficacy with drug than placebo. In conclusions, there is a paucity of published controlled antidepressant trials in the elderly. Most published studies examine small sample sizes and do not include common comorbid conditions. Efficacy studies examining relapse prevention are lacking. Large placebo response rates, lack of controlled head to head comparisons, and other methodological design differences make crosstrial comparisons difficult. Large simple studies are urgently needed to address the unmet needs for data on safety and efficacy of antidepressants in this population.

show abstract

Section: Methodological Considerations For Antidepressant Trials In Tmentioning

confidence: 99%

A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future

Taylor

Doraiswamy

2004

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…46 Its sensitivity and specificity have been shown to be superior to that of the BDI and SDS, 46 and similar to the MADRS. 47 It has good test-retest and interrater reliability, although item reliability is poor. 46 Semistructured versions have been developed, including scoring guidelines that improved item reliability.…”

Section: Depression In Non-pd Patientsmentioning

confidence: 99%

“…60 Cutoff scores of 9/10 60 and 11/12 47 to screen for dPD, and 15/16 60 and 13/14 47 to diagnose major depressive disorder (although diagnosis using a scale alone is not recommended) have been suggested. Using these cutoffs, sensitivity, specificity, and positive and negative predictive values for a DSM-IV diagnosis of major depressive disorder in PD have been found to be acceptable.…”

Section: Depression In Pdmentioning

confidence: 99%

“…Cutoff scores in PD of 14/15 for screening (high sensitivity and high NPV) and 17/18 (high specificity and high PPV) for diagnostic purposes have been validated in PD against a diagnosis of major depressive disorder. 47 It has been used in medication trials in dPD and been shown to be sensitive to change in the level of severity of depression. 73,81 It has also been used to assess the phenomenology of dPD.…”

Section: Depression In Pdmentioning

confidence: 99%

See 1 more Smart Citation

Depression rating scales in Parkinson's disease: Critique and recommendations

Schrag¹,

Barone²,

Brown³

et al. 2007

Movement Disorders

592

348

View full text Add to dashboard Cite

Depression is a common comorbid condition in Parkinson's disease (PD) and a major contributor to poor quality of life and disability. However, depression can be difficult to assess in patients with PD due to overlapping symptoms and difficulties in the assessment of depression in cognitively impaired patients. As several rating scales have been used to assess depression in PD (dPD), the Movement Disorder Society commissioned a task force to assess their clinimetric properties and make clinical recommendations regarding their use. A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected for this review. The scales reviewed were the Beck Depression Inventory (BDI), Hamilton Depression Scale (Ham-D), Hospital Anxiety and Depression Scale (HADS), Zung Self-Rating Depression Scale (SDS), Geriatric Depression Scale (GDS), Montgomery-Asberg Depression Rating Scale (MADRS), Unified Parkinson's Disease Rating Scale (UPDRS) Part I, Cornell Scale for the Assessment of Depression in Dementia (CSDD), and the Center for Epidemiologic Studies Depression Scale (CES-D). Seven clinical researchers with clinical and research experience in the assessment of dPD were assigned to review the scales using a structured format. The most appropriate scale is dependent on the clinical or research goal. However, observer-rated scales are preferred if the study or clinical situation permits. For screening purposes, the HAM-D, BDI, HADS, MADRS, and GDS are valid in dPD. The CES-D and CSDD are alternative instruments that need validation in dPD. For measurement of severity of depressive symptoms, the Ham-D, MADRS, BDI, and SDS scales are recommended. Further studies are needed to validate the CSDD, which could be particularly useful for the assessment of severity of dPD in patients with comorbid dementia. To account for overlapping motor and nonmotor symptoms of depression, adjusted instrument cutoff scores may be needed for dPD, and scales to assess severity of motor symptoms (e.g., UPDRS) should also be included to help adjust for confounding factors. The HADS and the GDS include limited motor symptom assessment and may, therefore, be most useful in rating depression severity across a range of PD severity; however, these scales appear insensitive in severe depression. The complex and time-consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted.

show abstract

“…Major depression and dysthymia were our outcomes of interest. The severity of depression in patients was assessed by the criteria of the Hamilton Depression Rating Scale (HAMD -17) 14) , and a score ≥14 was defined as "depression" 15) .…”

Section: Methodsmentioning

confidence: 99%

Heavy Metals in Blood and Urine and Its Relation to Depressive Symptoms in Parkinson's Disease Patients

Fukushima

Tan

Luo

et al. 2013

Fukushima J. Med. Sci.

View full text Add to dashboard Cite

: Objectives Some heavy metals are suspected to be pathogenic to both Parkinson's disease (PD) and depression. Common background may exist in them. Methods Subjects comprised PD patients with depression, PD patients without depression and controls recruited from the outpatient clinic in China. Morning blood and urine samples were used to measure concentrations of metals and vitamins. Results Whole -blood manganese was significantly higher in the PD patients without depression than in both the PD patients with depression and the controls. Serum iron was significantly higher in the PD patients without depression than in the controls. Urine iron was also significantly higher in the PD patients without depression than in the controls. Serum copper was significantly lower in the PD patients with depression than in both the PD patients without depression and the controls. Conclusions Excessive intake of iron and accumulation of manganese seemed to be involved in the etiology of non -depressive PD.

show abstract

The validity of the Hamilton and Montgomery-�sberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease

Cited by 262 publications

References 30 publications

A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future

A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future

Depression rating scales in Parkinson's disease: Critique and recommendations

Heavy Metals in Blood and Urine and Its Relation to Depressive Symptoms in Parkinson's Disease Patients

Contact Info

Product

Resources

About